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Up to 90% of patients with a myelodysplastic syndrome requirered blood cell transfusion; nevertheless, comprehensive data onred cell alloimmunization in such patients are limited. This study
evaluates the incidence and clinical impact of red cell alloimmunization
in a large cohort of patients with myelodysplastic syndrome registered in
the statewide South Australian-MDS registry. The median age of the 817
patients studied was 73 years, and 66% were male. The cumulative inci-
dence of alloimmunization was 11%. Disease-modifying therapy was
associated with a lower risk of alloimmunization while alloimmuniza-
tion was significantly higher in patients with a revised International
Prognostic Scoring System classification of Very Low, Low or
Intermediate risk compared to those with a High or Very High risk
(P=0.03). Alloantibodies were most commonly directed against antigens
in the Rh (54%) and Kell (24%) systems. Multiple alloantibodies were
present in 49% of alloimmunized patients. Although 73% of alloimmu-
nized patients developed alloantibodies during the period in which they
received their first 20 red cell units, the total number of units transfused
was significantly higher in alloimmunized patients than in non-alloim-
munized patients (90±100 versus 30±52; P<0.0001). In individual
patients, red cell transfusion intensity increased significantly following
alloimmunization (2.8±1.3 versus 4.1±2.0; P<0.0001). A significantly
higher proportion of alloimmunized patients than non-alloimmunized
patients had detectable autoantibodies (65% versus 18%; P<0.0001) and
the majority of autoantibodies were detected within a short period of
alloimmunization. In conclusion, this study characterizes alloimmuniza-
tion in a large cohort of patients with myelodysplastic syndrome and
demonstrates a signficant increase in red cell transfusion requirements
following alloimmunization, most probably due to development of addi-
tional alloantibodies and autoantibodies, resulting in subclinical/clinical
hemolysis. Strategies to mitigate alloimmunization risk are critical for
optimizing red cell transfusion support. 
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ABSTRACT
Introduction
Myelodysplastic syndromes (MDS) are clonal diseases
characterized by peripheral cytopenias, ineffective
hematopoiesis and an increased risk of leukemic transfor-
mation.1 They are among the most commonly diagnosed
myeloid malignancies2 with the median age of affected
individuals at diagnosis being 72 years.3 Management
options include disease-modifying therapies and support-
ive measures such as red blood cell (RBC) and platelet
transfusions, antimicrobials and growth factors.4,5
Transfusion support remains a cornerstone of manage-
ment for most MDS patients. Up to 90% of patients
require RBC transfusions during the course of their dis-
ease6 and 30-45% become dependent on RBC transfu-
sions.7,8 
Importantly, RBC transfusion dependency is associated
with a significantly worse survival independently of the
revised International Prognostic Scoring System (IPSS-R)
risk score. MDS patients are at high risk of developing
transfusion-associated complications such as iron over-
load and acute or delayed hemolytic transfusion reactions,
resulting in significant morbidity and mortality.9 True mor-
bidity and mortality burden from RBC alloimmunization
is likely higher than reported to hemovigilance pro-
grams.10,11 Alloimmunization may also drive RBC autoan-
tibody formation and subclinical/serological hemolytic
transfusion reactions.12 Although RBC autoantibody for-
mation after alloimmunization can occur in any transfused
patient, reported rates are much higher in transfused
patients with thalassemia or sickle cell disease with a
cumulative incidence of 6-10%.13-16 In a study of 717
patients with autoantibodies, 200 (28%) patients had both
autoantibodies and alloantibodies, and the majority were
detected simultaneously and were induced by
transfusion.17 We have observed clinically that some MDS
patients have increased RBC transfusion requirement fol-
lowing development of alloimmunization. For the transfu-
sion service, identifying and characterizing allo- and
autoantibodies can be time-consuming, laborious and
expensive and can cause difficulties and delay in finding
compatible units.
Despite the high prevalence of MDS, data on alloimmu-
nization in chronically transfused MDS patients mostly
reflect experience from single centers with limited num-
bers of patients and often relatively short follow-up.18-20
Highly variable alloimmunization rates have been report-
ed.18-20 Larger studies are required to better understand
alloimmunization in MDS, including the complex inter-
play between disease- and patient-related factors, and
transfusion burden. This study characterizes RBC alloim-
munization in a large series of well-annotated patients
with MDS followed in a state-wide MDS registry. 
Methods
The South Australian MDS Registry has been described
previously.7 Briefly, it is a comprehensive, state-wide
database of adult patients with MDS, MDS/myeloprolif-
erative neoplasm overlap syndrome, acute myeloid
leukemia (<30% blasts) and therapy-related myeloid neo-
plasm from six participating hospitals across the public
and private sectors (Online Supplementary Methods).
Institutional ethics committee approval was obtained
from all participating institutions and procedures were
performed in accordance with the revised Helsinki
Declaration.
Demographic, clinical, laboratory and treatment
(including transfusions) details of patients diagnosed
between 1990 and 2015 enrolled in the registry and with
at least 6 months of follow-up were analyzed. Disease-
modifying therapies included azacitidine, lenalidomide,
intensive chemotherapy and allogeneic hematopoietic
stem cell transplantation. 
RBC transfusion dependency was defined as the
requirement of at least one RBC unit every 8 weeks over
a 4-month period.7,8 As some patients received RBC trans-
fusions before their MDS diagnosis had been established,
we assessed the serial blood counts, clinical profile and
RBC transfusion requirements of all patients before and
after MDS diagnosis. RBC units transfused before the
diagnosis of MDS were considered MDS-related if a
patient was transfused to alleviate persistent or progres-
sive anemia due to MDS. RBC units transfused before the
MDS diagnosis for other causes, such as gastrointestinal
bleeding, surgery or trauma, were considered unrelated. 
To minimize the influence of clinical variables such as
infection, bleeding, disease-modifying therapies and inva-
sive procedures, we evaluated transfusion intensity (num-
ber of RBC units transfused per month) in patients requir-
ing regular RBC transfusion before and after alloimmu-
nization during the entire study period, and over a fixed
period of 8 months (4 months before and 4 months after
first documentation of alloimmunization). Patients who
received disease-modifying therapies, died or progressed
to acute myeloid leukemia within 4 months of alloimmu-
nization were excluded, as these variables would influ-
ence RBC transfusion intensity. Patients who developed
alloantibodies before MDS-related transfusion, devel-
oped alloantibodies after only one or two episodes of
RBC transfusion, received only intermittent RBC transfu-
sions, or did not receive further RBC transfusion after
alloantibodies had been detected were also excluded
from this analysis as RBC transfusion intensity could not
be calculated accurately in these patients.  
Laboratory data included patients’ ABO/Rh type, anti-
body screening results, direct antiglobulin test and alloan-
tibody and autoantibody specificities (where specificity
was documented). Data concerning transfusion reactions
were obtained from the hospitals’ transfusion records
(Online Supplementary Methods). A delayed serological
transfusion reaction was considered to have occurred if
all the following criteria were satisfied: (i) a new antibody
was detected; (ii) there was a new positive direct
antiglobulin test, (iii) RBC elution identified the presence
of the same antibody that was identified in the serum;
and (iv) phenotyping of the patient’s RBC demonstrated
mixed-field typing or negativity for the antigen towards
which the alloantibody in the patient’s serum/eluate was
directed. A delayed hemolytic transfusion reaction was
defined as having occurred when a patient with a delayed
serological transfusion reaction had clinical evidence of
hemolysis.21,22
The cumulative incidence of alloimmunization was
analyzed by competing-risks regression using the Fine
and Gray method. Factors associated with RBC alloanti-
body formation were investigated using random survival
forest, recursive partitioning and competing risk regres-
sion analyses (Online Supplementary Methods).
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Results
Patient and clinical characteristics
The clinical and laboratory records of 836 MDS patients
were reviewed. Nineteen patients were ineligible for fur-
ther analysis because of inadequate follow up and/or
incomplete transfusion history. The median age of the 817
patients eligible for analysis was 73 years (range, 19-98
years); 536 (66%) patients were male. MDS-multilineage
dysplasia, MDS with excess blasts-1  and MDS with
excess blasts-2 were the most frequent subtypes (Table 1).
The majority of patients received supportive care alone
(605; 74%) while 204 (25%) patients received disease-
modifying therapies (Table 1).
According to IPSS-R score, 457 (56%) patients were
classified in the Very Low, Low and Intermediate risk
groups, while 179 (22%) patients were classified in the
High and Very High risk groups, with significant differ-
ences in survival and cumulative incidence of RBC trans-
fusion dependency between the groups (Table 1; Online
Supplementary Figure S1A,B). The 132 (16%) patients with
therapy-related myeloid neoplasm or proliferative MDS/
myeloproliferative neoplasm overlap were not eligible for
IPSS-R calculations. IPSS-R could not be assessed in 49
(6%) patients because of missing data or failed metaphase
cytogenetics. 
Incidence of red blood cell alloimmunization 
During the study 695 (85%) patients received at least
one unit of RBC, and 98 (12%) patients developed 175
alloantibodies. Of these, seven patients developed anti-
bodies before their first documented RBC transfusion
and 11 patients developed alloantibodies following
MDS-unrelated RBC transfusion before the diagnosis of
MDS (range, 0.23 to 146 months prior) (Online
Supplementary Table S1). The remaining 80 patients
(including six patients who were also transfused before
MDS diagnosis) developed alloantibodies following
MDS-related RBC transfusion (Online Supplementary
Table SI). Thus, the cumulative incidence of RBC alloim-
munization with death as a competing risk was 11% at
50 months following the first MDS-related RBC transfu-
RBC alloimmunization in MDS patients
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Figure 1. Cumulative incidence of red blood cell alloimmunization and time to development of alloantibodies. (A) Probability of alloimmunization with death as com-
peting risk by months following first RBC transfusion; (B) 73% of alloimmunized patients developed alloantibodies within the period of transfusion of their first 20
units of RBC; (C) 50% of alloimmunized patients developed alloantibodies within 6 months after their first RBC transfusion.
A B C
Table 1. Clinical features of patients included in the analysis.
Variable                                                        Number of patients (%)
Total                                                                                            817
Male/female                                                             536 (66%) / 281 (34%)
Age; median (range)                                                   73 (19-98) years
MDS subtype (WHO 2016 classification)
MDS-SLD                                                                              51 (6.2%)
MDS-MLD                                                                           186 (22.8%)
MDS-RS-SLD                                                                        36 (4.4%)
MDS-RS-MLD                                                                      37 (4.5%)
MDS-EB-1                                                                            89 (10.9%)
MDS-EB-2                                                                            83 (10.2%)
MDS with isolated del(5q)                                               17 (2.1%)
Hypoplastic MDS                                                                13 (1.6%)
MDS/MPN-U                                                                         18 (2.2%)
MDS/MPN RS-T                                                                    7 (1.0%)
MDS-U                                                                                    6 (0.7%)
CMML-0                                                                                42 (5.1%)
CMML-1                                                                                31 (3.8%)
CMML-2                                                                                20 (2.4%)
AML (<30% blasts)                                                            55 (6.7%) 
T-MN                                                                                    126 (15.4%)
IPSS-R categories
Very low                                                                              118 (14.4%)
Low                                                                                      216 (26.4%)
Intermediate                                                                     123 (15.1%)
High                                                                                       91 (11.1%)
Very high                                                                              88 (10.8%)
Not applicable                                                                   132 (16.2%)
Missing data                                                                         49 (6.0%)
Treatment for MDS
Disease-modifying therapy                                            204 (25.0%) 
Supportive care                                                                605 (74.0%)
Data missing                                                                          8 (1%)
The revised International Prognostic Scoring System (IPSS-R) is not applicable to
cases of T-MN, proliferative CMML and MDS/MPN overlap syndrome (n=132). In 49
(6.0%) cases, minimal data for calculating IPSS-R were not available. MDS-SLD: MDS
with single lineage dysplasia; MDS-MLD: MDS with multilineage dysplasia; MDS-RS-
SLD: MDS with ring sideroblasts with single lineage dysplasia; MDS-RS-MLD: MDS with
ring sideroblasts with multilineage dysplasia; MDS-EB-1: MDS with excess blasts-1;
MDS-EB-2: MDS with excess blasts-2; MDS/MPN-U: MDS/myeloproliferative neoplasms,
unclassifiable; MDS/MPN-RS-T: MDS/MPN with ring sideroblasts and thrombocytosis;
MDS-U: MDS, unclassifiable; CMML: chronic myelomonocytic leukemia; AML: acute
myeloid leukemia; T-MN: therapy-related myeloid neoplasms.
sion (Figure 1A). Importantly, 73% and 50% of alloim-
munized patients developed alloantibodies following
transfusions of fewer than 20 RBC units (Figure 1B;
Online Supplementary Figure S1C) and during the first 6
months following commencement of RBC transfusions
(Figure 1C), respectively.
Of the 98 patients who developed RBC alloantibodies,
50 (51%) patients developed one alloantibody, while 48
(49%) developed multiple alloantibodies, including four
patients who developed four antibodies each, and one
patient who developed six antibodies in total. Fourteen
and three patients developed two and three antibodies
simultaneously, respectively (Table 2 and Online
Supplementary Table S1). 
Rh (54%) and Kell (24%) system antibodies were the
most frequent, followed by Kidd (7.5%) and Lutheran
(5.7%) system antibodies (Table 2 and Online
Supplementary Table S1). Within the Rh group, anti-E
(46%) was the most frequent, followed by anti-C (17%)
and anti-D (17%) (Table 2). Despite our state-wide poli-
cy of providing RhD-compatible RBC transfusions, 16
RhD-negative patients developed anti-D. These patients’
transfusion records were reviewed for the period prior to
anti-D alloimmunization. Anti-D was detected following
RhD-positive platelet transfusions in eight patients (one
to two units of platelets), and three patients received
RhD-positive RBC units due to a clinical emergency. In
three female patients, the anti-D alloimmunization was
most probably pregnancy-related. For the remaining two
patients, we could find no record of RhD-positive
platelet or RBC transfusion. Administration of anti-D Rh
immunoglobulin remains a possibility, but we could not
find any record of it in the participating institutions.
Autoantibody formation following alloimmunization
During the study period, 327 (40%) patients had a direct
antiglobulin test performed and the test was positive at
least once in 157 (48%) patients. Alloimmunized patients
had much higher rates of positive direct antiglobulin test
(84% versus 33%, P<0.0001; Online Supplementary Figure
S1D) and reactive eluates (80% versus 18%, P<0.0001,
Figure 2A) than non-alloimmunized patients. RBC eluates
showed pan-agglutination due to non-specific autoanti-
body, an alloantibody, a combination of an allo- and
autoantibody, and non-reactivity in 52%, 15%, 13%, and
19% of alloimmunized patients, respectively. Thus, a sig-
nificantly higher proportion of alloimmunized patients had
detectable autoantibody compared to non-alloimmunized
patients (65% versus 18%; P<0.0001) (Figure 2A).
Circulating free autoantibody was also detected in 31/51
(61%) of alloimmunized patients. 
In the 88% of alloimmunized patients who developed
autoantibodies, these were detected either at the time of
alloimmunization or within the 5 months preceding or
following alloimmunization (Online Supplementary Figure
S1E). In two cases in which autoantibody was detected
74 and 18 months prior to alloantibody detection, the
patients were diagnosed with warm autoimmune
hemolytic anemia on the background of non-Hodgkin
lymphoma or chronic lymphocytic leukemia. In one
female patient, the autoantibody was detected at the
time that chronic lymphocytic leukemia was diagnosed,
107 months after the alloantibody had first been detect-
ed. In this case, the alloantibody was most probably
related to a previous pregnancy.
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Table 2. Alloantibody specificities.
Alloantibody specificity(ies)               N. of patients affected (%)
                                                                   (total n=98)
Single alloantibody:                                       50 (51%)
E                                                                                               16 (16%)
K                                                                                               10 (10%)
Kp(a)                                                                                       5 (5.1%)
Lu(a)                                                                                       5 (5.1%)
C                                                                                               3 (3.1%)
c                                                                                                 1 (1%)
D                                                                                               3 (3.1%)
Jk(a)                                                                                        3 (3.1%)
M                                                                                                2 (2%)
C(w)                                                                                          1 (1%)
Le(a)                                                                                         1 (1%)
Low incidence antigen                                                          1 (1%)
Two alloantibodies:                                        26 (27%)
C + D                                                                                       3 (3.1%)
E + c                                                                                        3 (3.1%)
E + Jk(a)                                                                                 1 (1%)
E + Yt(b)                                                                                 1 (1%)
Jk(a) + E                                                                                 1 (1%)
Jk(a) + Lu(a)                                                                         1 (1%)
c + Kp(a)                                                                                 1 (1%)
D + C                                                                                        1 (1%)
C + E                                                                                         1 (1%)
D + E                                                                                        1 (1%)
K + Kp(a)                                                                                1 (1%)
E + K                                                                                         1 (1%)
C + Lu(a)                                                                                 1 (1%)
Co(b) + D                                                                                1 (1%)
K + C                                                                                         1 (1%)
C + Kp(a)                                                                                1 (1%)
E + Kp(a)                                                                                1 (1%)
D + Jk(a)                                                                                 1 (1%)
K + S                                                                                         1 (1%)
K + HLA                                                                                    1(1%)
Le(a) + HLA                                                                            1(1%)
Fy(a) + K                                                                                 1 (1%)
Three or more alloantibodies:                      22 (23%)
D + Jk(a) + E                                                                         1 (1%)
E + Fy(b) + Jk(a)                                                                 1 (1%)
Jk(a) + Co(b) + Cs(a)                                                        1 (1%)
E + K + c                                                                                 1 (1%)
D + K + Kp(a)                                                                        1 (1%)
E + C(w) + S                                                                          1 (1%)
C(w) + E + K                                                                          1 (1%)
C(w) + K + Lu(a)                                                                 1 (1%)
D + E + C                                                                                1 (1%)
C + D + Fy(a)                                                                         1 (1%)
C(w) + E + c                                                                          1 (1%)
E + M + S                                                                                1 (1%)
E + Lu(a) + c                                                                         1 (1%)
K + C + E                                                                                1 (1%)
E + c + Jk(a)                                                                          1 (1%)
E + K + Kp(a)                                                                        2 (2%)
D + E + Jk(b) + C                                                                 1 (1%)
E + Kp(a) + K + c                                                                 1 (1%)
K + Kp(a) + C(w) + Lu(a)                                                 1 (1%)
E + K + D + C                                                                        1 (1%)
E + c + Kp(a) + Jk(a) + S + C(w)                                  1 (1%)
Clinical consequences of antibody formation
Two patients developed significant hemolysis after
alloimmunization. A 51-year old male patient developed
an alloantibody resulting in life-threatening delayed
hemolytic transfusion reactions, cardiac arrest, multiorgan
failure and a prolonged stay in the Intensive Care Unit
(Online Supplementary Figure S2A-C). Another 83-year old
male patient developed hemolysis after 6 months of RBC
transfusion. Investigations revealed alloantibody, panag-
glutinating autoantibody and autoimmune hemolysis,
which responded to steroids (Online Supplementary Figure
S2D-F). Of the 79 alloimmunized cases with a positive
direct antiglobulin test, 22 (28%) satisfied the definition of
delayed serological transfusion reaction but were not
reported to the transfusion services as having had such a
reaction or a delayed hemolytic transfusion reaction.
Other transfusion reactions were generally infrequent,
mild in nature and limited to febrile non-hemolytic trans-
fusion reactions or allergic reactions. Fifteen alloimmu-
nized patients had 18 episodes of transfusion reactions
including 13 febrile non-hemolytic transfusion reactions
and five allergic reactions.
Alloimmunization increases red blood cell transfusion
intensity
The total number of RBC units transfused in alloimmu-
nized patients was significantly higher than in non-alloim-
munized patients (90±100 versus 30±52; P<0.0001) (Figure
2B). In alloimmunized patients the total number of RBC
transfused after alloimmunization was significantly higher
than the number before alloimmunization (P<0.0001)
(Figure 2C). RBC transfusion intensity was compared in 33
individual patients eligible for analysis before and after
alloimmunization (Online Supplementary Figure S3). RBC
transfusion intensity was significantly higher following
documentation of alloimmunization than prior to alloanti-
body formation (2.8±1.3 versus 4.1±2.0 units per month;
P<0.0001) (Figure 2D). To further minimize the impact of
other variables, we also compared RBC transfusion inten-
sity over a period of 8 months (4 months before and after
detection of alloimmunization). In this analysis, RBC trans-
fusion intensity was also significantly higher following
alloimmunization (3.6±2.2 versus 4.1±1.8 units per month;
P=0.01) (Figure 2E). Reticulocyte response, as expected,
was poor. In these patients, there was no clinically signifi-
cant different variation in platelet and neutrophil counts
during the period of analysis (data not shown). Lactate dehy-
drogenase and bilirubin levels transiently increased in
some patients after alloimmunization (data not shown).
Haptoglobin results were not available. 
Risk factors for alloimmunization
To identify potential predictors of alloimmunization
676 patients, including 80 who developed alloantibodies
following MDS-related RBC transfusions, were included
in random survival forest and recursive partitioning analy-
ses. The number of RBC units transfused before alloanti-
body formation was the most important predictor of
alloimmunization, followed by RBC transfusion depend-
ency status, treatment type, and age (Figure 3A-C). A clas-
sification tree using recursive partitioning suggested that
46% (39/84) patients who were dependent on RBC trans-
RBC alloimmunization in MDS patients
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Figure 2. Alloimmunization is associated with
autoantibody formation and increased red blood
cell transfusion requirement. (A) Autoantibodies
were detected in a significantly higher number of
alloimmunized patients than in non-alloimmunized
ones (65% vs. 18%; P<0.0001) (B) The total number
of RBC units transfused was significantly higher in
alloimmunized patients than in non-alloimmunized
patients (P<0.0001) (C) In alloimmunized patients,
the total number of RBC units transfused was signif-
icantly higher after alloimmunization (D) RBC trans-
fusion intensity was significantly higher following
alloimmunization during the whole study period (E)
RBC transfusion intensity compared over 8 months
(4 months before and 4 months after alloimmuniza-
tion) also confirmed that RBC transfusion intensity
increases significantly following alloimmunization.
A B C
D E
fusions developed an alloantibody within the period they
were given their first 20 units of RBC (hazard ratio 5; node
7). In the random survival forest analysis, the predicted
error rate was 26%, indicating a 74% chance of correctly
predicting alloimmunization risk with a tree constructed
from the five factors shown in Figure 3A,B. 
As 73% and 50% of alloimmunized patients developed
alloantibodies within the initial 20 units of RBC and with-
in 6 months after their first RBC transfusion, we per-
formed landmark analyses using a competing risk regres-
sion model both at baseline and at 6 months following the
start of RBC transfusions. For the baseline analysis age,
sex, WHO subtype, IPSS-R risk groups and type of treat-
ment were included. For the 6-month analysis numbers of
RBC units transfused within 6 months and RBC transfu-
sion dependency status at 6 months were included, in
addition to all the baseline factors. 
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Figure 3. Recursive partition and random forest analysis to identify patients at higher risk of alloimmunization. (A-B) The random forest analysis predicted an error
rate of 26%, thus indicating a 74% chance of correctly predicting alloimmunization risk. RBC units transfused prior to alloantibody, RBC-TD status and treatment type
are major predictors of alloimmunization (C) Recursive partition analysis incorporating these variables produced a classification tree demonstrating that the majority
of alloimmunized patients developed antibody within the first 20 units of RBC transfusion. Alloimmunization risk was highest in RBC-TD patients within the initial 20
units of RBC (hazard ratio 5; node 7) (D) Cumulative incidence of alloimmunization was significantly lower in patients treated with DMT (E) Cumulative incidence of
alloimmunization was significantly higher in RBC-TD IPSS-R Very Low, Low, intermediate risk groups compared to RBC-TD High and Very High risk groups, while alloim-
munization was significantly lower in RBC-TI patients in both groups. In Figure 3C: top, middle and bottom values in each node (box) indicate hazard ratio (HR), num-
ber of cases developing alloantibody divided by number of cases in that group and percentage of total cases, respectively. For example in node 7, the HR of devel-
oping an alloantibody was 5 (top number), 39/84 cases developed alloantibodies and this node represents 12% of the total cases. IPSS-R categories are Very Low
(VL), Low (L), Intermediate (I), High (H), and Very High (VH). T-MN: therapy-related myeloid neoplasm; MDS/MPN overlap myelodysplastic/myeloproliferative neoplasm
overlap syndrome. DMT: disease-modifying therapy; BSC: best supporting care; RBC-TD: RBC transfusion dependency; RBC-TI: RBC transfusion independent.
A C
B D E
Table 3. Competing risk regression analysis for alloimmunization.
Variables                                   Baseline                    6-month landmark analysis 
                                 Hazard ratio      P value             Hazard ratio       P value
Treatment                            0.248                0.0013                         0.236                  0.019
IPSS-R*                                0.628                  0.14                           0.273                  0.035
Age at diagnosis                  1.02                   0.15                            1.02                     0.16
Sex                                          1.35                   0.26                            1.48                     0.32
MDS-subtype                       1.57                   0.26                            2.49                     0.09
RBC-transfusion                    -                         -                               0.87                      0.7
dependency
Number of RBC                     -                         -                              0.997                   0.78
units transfused
by 6 months
IPSS-R*: Very Low, Low and Intermediate risk groups were grouped together while
High and Very High risk were grouped together.
At the baseline and 6-month landmark analyses, alloim-
munization risk was significantly lower in patients treated
with disease-modifying therapies (hazard ratio 0.24;
P=0.0013) (Table 3). The cumulative incidences of alloim-
munization at 50 months (4% versus 14%) and 100
months (5% versus 15%) were significantly lower in
patients treated with disease-modifying therapies than in
those given supportive care only (P<0.001) (Figure 3D) and
appeared to be unrelated to number of RBC transfusions,
as patients treated with disease-modifying therapies
received significantly more RBC units prior to alloanti-
body detection than patients treated with supportive care
(42.5±44 versus 35±54.6; P<0.0001) (Online Supplementary
Figure S4A). Within the group given disease-modifying
therapies, the rate of alloimmunization was significantly
higher in patients treated with azacitidine/lenalidomide
than in those treated with intensive chemotherapy and/or
allogeneic hematopoietic stem cell transplantation (2.9%
versus 0% at 12 months, P=0.02) (Online Supplementary
Figure S4B). At the 6-month landmark, IPSS-R groups also
predicted alloimmunization; the cumulative incidence of
alloimmunization was significantly higher in patients in
the combined IPSS-R Very Low, Low and Intermediate
risk groups than in those in the combined High and Very
High risk groups (P=0.03). The cumulative incidence of
alloimmunization was significantly higher in RBC transfu-
sion-dependent patients in IPSS-R Very Low, Low and
Intermediate risk groups than in RBC transfusion-depen-
dent patients in IPSS-R High and Very High risk groups.
The incidence of alloimmunization was significantly
lower in RBC-transfusion-independent groups (Figure 3E). 
Discussion
Post-transfusion RBC alloimmunization rates vary from
2.5-3.3% for surgical patients to 9-13% in patients with
hematologic malignancies.18,23-25 In a large study of more
than 21,000 previously non-transfused patients who
received RBC transfusions without extended matching,
alloantibodies were detected in 2.2% of all transfused
patients with a cumulative alloimmunization incidence of
7.7% after 40 units.26 In MDS, highly variable alloimmu-
nization rates have been reported, ranging from 15 to
59%,18-20,27-30 which may reflect small cohorts of patients,
inconsistent inclusion criteria and variable follow-up peri-
ods. Of these, studies with smaller numbers of patients
reported higher alloimmunization rates of 44 to 57%,18,20,30
while a study of 272 patients reported an alloimmuniza-
tion rate of only 15%.19 This is similar to the 11% cumu-
lative incidence of alloimmunization in our study, which,
to the best of our knowledge, is the largest of its type and,
crucially, was also able to distinguish between alloimmu-
nization due to MDS-related and unrelated RBC transfu-
sions. Importantly, this is the first study demonstrating a
significant increase in RBC transfusion requirements fol-
lowing alloimmunization in MDS patients.  
In our study 76% of alloimmunized patients developed
antibodies against antigens in the Rh and Kell systems,
similar to the 62% reported in MDS by Sanz et al.,19 and
consistent with observations made in studies of patients
with sickle cell disease and thalassemia31,32 and medical
patients.26 Differences in immunogenic RBC antigens
between donors and recipients also play a role in alloim-
munization. These disparities are unlikely to be a major
contributor to alloimmunization in our cohort of patients
with MDS as the vast majority of the recipients and
donors in our cohort were Caucasian.
The life expectancy of some higher risk MDS patients is
short and, overall, only 11% of transfused MDS patients
developed alloantibodies. It is, however, of considerable
interest from clinical and cost-effectiveness standpoints to
identify the patients at highest risk of RBC alloimmuniza-
tion, because they would be the ones to benefit most from
a policy of extended antigen-matched RBC transfusions.
Although the number of RBC units transfused increases
the risk of alloimmunization,19 RBC transfusion require-
ment is dynamic. We found that 73% of patients develop-
ing alloantibodies did so within the period of receiving
their first 20 units of RBC and 50% of patients within 6
months of their first RBC transfusion. Hence, it is critical
to identify patient- and disease-related factors that will
differentiate between “responders” and “non-responders”
to RBC antigens. 
In our study, disease-modifying therapies predicted
alloimmunization risk at both the baseline and 6-month
landmark analyses. Interestingly, the cumulative inci-
dence of alloimmunization was significantly lower in
patients treated with intensive chemotherapy and/or allo-
geneic hematopoietic stem cell transplantation compared
to that in patients treated with azacitidine/lenalidomide,
possibly due to the greater degree of immunosuppres-
sion. Lower alloimmunization rates in IPSS-R High and
Very High risk groups compared to Very Low, Low and
Intermediate risk groups could be due to the shorter
median overall survival, larger proportion of patients
requiring disease-modifying therapies, and greater degree
of immunosuppression in higher risk groups. Within each
group, alloimmunization risk was significantly higher
among the RBC transfusion-dependent group compared
to the transfusion-independent group, while alloimmu-
nization rate was similarly low in RBC transfusion-inde-
pendent regardless of risk and treatment assignment. The
number of regulatory T cells, known to inhibit alloimmu-
nization, is significantly lower in IPSS low risk patients
than in IPSS high risk patients.33,34
This study focused on the clinical implications of
alloimmunization, but alloimmunization also leads to
increased laboratory workloads and poses the challenge
of securing appropriate RBC units in a timely fashion.
The clinical consequences of alloimmunization in our
study included at least two cases of severe delayed
hemolytic transfusion reaction, 22 cases of delayed sero-
logical transfusion reaction, and increased RBC transfu-
sion requirements. RBC transfusion requirement
increased following alloimmunization, most likely due to
the development of additional alloantibodies and autoan-
tibodies, resulting in subclinical serological hemolytic
transfusion reactions and/or autoimmune hemolysis.
Notably, autoantibodies were detected before, simultane-
ously or within a short time after alloimmunization. This
suggests that alloimmunization drives autoantibody for-
mation. Young et al. detected autoantibodies in 121/2618
(4.6%) individuals with a positive direct or indirect
antiglobulin test.12 Interestingly, 41 (34%) of these individ-
uals had both alloantibodies and autoantibodies, and at
least 34% of cases developed RBC autoantibodies after
previous blood transfusion and in association with alloim-
munization.12 Similarly, other studies reported that 8% to
25% of multiply transfused patients with sickle cell dis-
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ease16 or thalassemia13 have IgG autoantibodies, mostly
associated with alloimmunization. RBC autoantibody for-
mation has also been described in both animal and human
experimental models of RBC transfusion.15 The patho-
physiological mechanisms are not yet fully understood.35
The implication of autoantibodies is two-fold. Firstly, they
pose challenges to the transfusion laboratory. Resolution
of these complex cases translates into a heavy workload,
delay in provision of transfusions and increased cost.
Secondly, autoantibodies can be pathological, causing
shortened RBC survival and autoimmune hemolysis,
which may be severe.13 In MDS patients, hemolysis
assessment can be complicated by higher (disease-related)
baseline lactate dehydrogenase and poor reticulocyte
response due to dyserythropoiesis. Since RBC transfusion
can also influence lactate dehydrogenase, haptoglobin and
bilirubin levels, a high degree of clinical suspicion is
required. The integration of RBC genotyping can mini-
mize or even potentially eliminate labor-intensive serolog-
ical testing and provide better matched RBC units.
Investigators at the Wisconsin Blood Center genotyped 42
blood group antigens in 43,066 blood donors and were
able to provide antigen-negative RBC for more than 94%
of requests. There were no cases of acute hemolytic trans-
fusion reaction, delayed hemolytic transfusion reaction,
alloimmunization or other adverse reactions.36
In summary, this large registry-based study shows that
RBC alloimmunization is not uncommon in MDS, occurs
early after commencing transfusion, and has important
clinical consequences, including an association with
increased RBC transfusion requirements. Provision of
extended phenotype-matched RBC units from initiation
of a transfusion program for MDS patients can minimize
alloimmunization30 and its complications and may be of
benefit.
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